All In Biotech

Drug Trial Radar · NCT02247804

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Jun 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 594 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

594

Actual

Start

Dec 15, 2014

Primary completion

Feb 19, 2018

Study completion Jul 19, 2019

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Conditions

  • Glaucoma, Open-Angle
  • Ocular Hypertension

Interventions

  • Bimatoprost SRDrug

    Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.

  • Active Comparator: Timolol 0.5%Drug

    Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.

  • Sham: Applicator Without NeedleOther

    Sham administered on Day 1, Week 16, and Week 32.

  • Timolol Vehicle (placebo)Drug

    Timolol vehicle administered once in the morning and once in the evening for up to 20 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in IOP in the Study Eye at Week 12 (Hours 0 and 2)Time frame: Baseline (Hours 0 and 2) to Week 12 (Hours 0 and 2)
  2. IOP in the Study Eye at Week 2 (Hour 0)Time frame: Week 2 (Hour 0)
  3. IOP in the Study Eye at Week 2 (Hour 2)Time frame: Week 2 (Hour 2)
  4. IOP in the Study Eye at Week 6 (Hour 0)Time frame: Week 6 (Hour 0)
  5. IOP in the Study Eye at Week 6 (Hour 2)Time frame: Week 6 (Hour 2)
  6. IOP in the Study Eye at Week 12 (Hour 0)Time frame: Week 12 (Hour 0)
  7. IOP in the Study Eye at Week 12 (Hour 2)Time frame: Week 12 (Hour 2)

Locations

106 sites in 14 countries. Site status is shown where the registry gives one.

  • Arizona Glaucoma Specialists

    Phoenix, Arizona

  • Lugene Eye Institute

    Glendale, California

  • Lakeside Vision Center

    Irvine, California

  • Hamilton Glaucoma Center, Shiley Eye Center UCSD

    La Jolla, California

  • Atlantis Eye Care

    Long Beach, California

  • Glaucoma Institute of Beverly Hills

    Los Angeles, California

  • Montebello Medical Eye Center Inc.

    Montebello, California

  • Stanford University

    Palo Alto, California

  • Foothill Eye Institute

    Pasadena, California

  • Martel Eye Medical Group

    Rancho Cordova, California

  • Grutzmacher, Lewis and Sierra, Inc.

    Sacramento, California

  • Pacific Eye Associates

    San Francisco, California

  • Eye Associates of Colorado Springs

    Colorado Springs, Colorado

  • Palm Beach Eye Center, INC

    Atlantis, Florida

  • Nature Coast Clinical Research

    Crystal River, Florida

  • Levenson Eye Associates

    Jacksonville, Florida

  • East Florida Eye Institute

    Stuart, Florida

  • International Research Center

    Tampa, Florida

  • Coastal Research Associates, LLC

    Roswell, Georgia

  • Chicago Eye Specialists

    Chicago, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • Heart of America Eye Care PA

    Shawnee Mission, Kansas

  • Tulane Medical Center

    New Orleans, Louisiana

  • Eye Doctors of Washington

    Chevy Chase, Maryland

  • MedRACS, LLC

    Quincy, Massachusetts

  • Ocular Immunology and Uveitis Foundation

    Waltham, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Minnesota Eye Constultants, P.A.

    Bloomington, Minnesota

  • Lifelong Vision Foundation

    Chesterfield, Missouri

  • Moyes Eye Center, PC

    Kansas City, Missouri

  • Northern New Jersey Eye Institute P.A.

    South Orange, New Jersey

  • Eyecare Ophthalmology Associates, PC

    Bethpage, New York

  • New York Eye and Ear Infirmary of Mount Sinai

    New York, New York

  • Rochester Ophthalmological Group PC

    Rochester, New York

  • 2000 North Village Avenue

    Rockville Centre, New York

  • Glaucoma Consultants of the Capital Region

    Slingerlands, New York

  • Montefiore Medical Center

    The Bronx, New York

  • 8 Medical Park Drive

    Asheville, North Carolina

  • Albemarle Clinical Trials, LLC

    Elizabeth City, North Carolina

  • University Hospitals of Cleveland

    Cleveland, Ohio

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.